Uterine Sarcomas in Patients Undergoing Surgery for Presumed Leiomyomas: 10 Years' Experience

Paul, P.G.; Rengaraj, Varsha; Das, Tanuka; Garg, Reena; Mh, Thomas; Khurd, Aditya S.

doi:10.1016/j.jmig.2015.11.012

Cited by 23 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found an incidence of subsequently diagnosed LMS of 0.3%. Other studies report occult LMS prevalence as 0.02–0.49% . When including menorrhagia as well as fibromas as an indication for hysterectomy in Norway, the actual incidence of occult LMS in laparoscopic hysterectomies was 0.08% during 2000–2012.…”

Section: Discussionmentioning

confidence: 95%

Uterine leiomyosarcoma – incidence, treatment, and the impact of morcellation. A nationwide cohort study

Skorstad

Kent

Lieng

2016

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

The most frequent symptom in women suffering from LMS was abnormal uterine bleeding [110/212 (51.9%)]. LMS was histopathologically verified in 49/212 (23.1%) preoperatively. In 48/212 (22.6%), a malignant condition was suspected and they were treated accordingly. In 115/212 (54.2%), malignancy was not suspected at time of surgery and the women were treated according to the treatment protocol for fibroids. In only four patients was tissue retrieval by power morcellation conducted, accounting for 1.9% of all LMS cases. Conclusions. In more than 50% of women suffering from LMS, a malignant diagnosis was not confirmed or suspected prior to surgery. In our material, power morcellation of LMS has not lead to reduced survival. We suggest that power morcellators may be used in surgical treatment of selected cases of premenopausal women with symptomatic, presumed benign uterine leiomyomas.

show abstract

Section: Discussionmentioning

confidence: 95%

Uterine leiomyosarcoma – incidence, treatment, and the impact of morcellation. A nationwide cohort study

Skorstad

Kent

Lieng

2016

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…The risk of occult ULMS is between 0.12% and 2.3% for women undergoing minimally invasive hysterectomy or myomectomy for benign indications. [ 4 , 7 , 8 ] All women with uterine smooth muscle tumors carry the risk of developing ULMS; however, the distribution of occult ULMS throughout overall ULMS, as well as all uterine smooth muscle tumors, is not clearly understood due to limited literature. In this context, the objective of this study was to obtain additional data by calculating the risk of overall and occult ULMS during gynecological procedures, which would improve the accuracy of such models and better inform patients.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and occult rates of uterine leiomyosarcoma

Wang

Zhang³

et al. 2020

Medicine

View full text Add to dashboard Cite

This study aimed to assess the prevalence and occult rates of uterine leiomyosarcoma (ULMS) in women with smooth-muscle tumors undergoing gynecological surgery. A retrospective study was performed at an academic cancer center from 2008 to 2015. Patients undergoing either hysterectomy or myomectomy via laparoscopic, abdominal, vaginal, and hysteroscopic approaches were identified with the validated pathology diagnosis of either ULMS or leiomyomas. All patients initially operated at our institute were included and reviewed. The prevalence and occult rates of ULMS were calculated and compared between different age groups. Twenty-eight patients with original ULMS were identified in 9556 gynecological surgeries. The prevalence of overall and occult ULMS in our study was 0.25% (1 in 345 patients) and 0.07% (1 in 1429 patients). The proportion of occult in all ULMSs was 25%. The prevalence rates of overall ULMS were 0.21%, 0.13%, 0.52%, 2.12%, and 6.67% in the 30 to 39, 40 to 49, 50 to 59, 60 to 69, and ≥70-year age groups, respectively. There was a significantly increased risk of ULMS after 50 years of age. The prevalence rates of occult ULMS were 0.05%, 0.08%, and 0.12% for the 30 to 39, 40 to 49, and 50 to 59 year age groups, respectively. There was no statistically significant difference among age the groups. The prevalence of ULMS was 0.41% and 0.16% for solitary and multiple tumor masses, respectively. Patients with solitary uterine tumors were at a significantly increased risk of ULMS (OR = 2.601, 95% CI = 1.108–6.141). Our retrospective data in part reflects the clinical characteristics of overall and occult ULMS and forms the basis for further prevention of occult ULMS.

show abstract

“…The median age of uterine LMS is older than 50 years, but about 20% cases were between 19 and 47 years . Uterine leiomyoma is a very common disease, but the incidence of LMS is reported to be 0.129–0.18% in presumed leiomyomas . In women who desire to preserve fertility, myomectomy would be usually chosen for the surgical treatment of leiomyoma, and it is essential to differentiate LMS from leiomyoma.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of combination serum assay of lactate dehydrogenase, D‐dimer, and C‐reactive protein for uterine leiomyosarcoma

Nishigaya

Kobayashi

Matsuzawa

et al. 2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

Uterine Sarcomas in Patients Undergoing Surgery for Presumed Leiomyomas: 10 Years' Experience

Cited by 23 publications

References 15 publications

Uterine leiomyosarcoma – incidence, treatment, and the impact of morcellation. A nationwide cohort study

Uterine leiomyosarcoma – incidence, treatment, and the impact of morcellation. A nationwide cohort study

Prevalence and occult rates of uterine leiomyosarcoma

Diagnostic value of combination serum assay of lactate dehydrogenase, D‐dimer, and C‐reactive protein for uterine leiomyosarcoma

Contact Info

Product

Resources

About